G

This pill supposed to boost libido after menopause is the subject of debate

For years, men have had the ability to enhance their desire and trigger reactions beneath their trousers with the famous blue pill. Women, however, had no equivalent on the market. Now, those entering menopause who seek to reclaim a youthful libido have their very own version of Viagra. While intimate pleasure knows no age, this pharmaceutical aphrodisiac is not without its critics.

What You Need to Know About the Controversial “Pink Pill”

Regarded by the medical community as a “small revolution,” Addyi is a female counterpart to the male Viagra, aimed at menopausal women under 65 who wish to “revitalize” their libido. Dubbed the “little pink pill,” a gendered name that suggests a lot, this medication, once reserved for premenopausal women, now targets a broader audience, promising a vibrant intimate life without interruptions. This initiative was made possible by the Food and Drug Administration, the American public health agency.

The effects of menopause are no longer a mystery: it extends far beyond occasional hot flashes and cessation of menstruation. This pivotal phase, marking the end of one life chapter and the beginning of another, often puts women’s bodies in a state of “suspension.” As the body recalibrates itself, it may become less responsive than before. What once provoked excitement now evokes indifference. Coupled with this biological reality are issues such as vaginal dryness, waning energy levels, mood fluctuations, and intimate discomfort. According to a report by the dating app Adam and Eve, 43% of women experience a decline in desire during menopause.

The “pink pill,” touted as more effective than ginger elixirs and maca concoctions, promises to help women with dwindling libido maintain their desire and “compensate” for biological disruptions. However, it is not a magical solution. Unlike Viagra, which mechanically enhances male function, Addyi influences neurotransmitters, particularly serotonin, the hormone associated with wellbeing.

Additional Pressure or a Genuine Need?

While a decrease in libido isn’t inherently a tragedy or an anomaly in need of fixing, it can lead to significant mental distress for some women. Experts refer to this as Hypoactive Sexual Desire Disorder (HSDD), where the desire to connect with one’s partner is present, but the body remains unresponsive, even to the most enticing of touches. It is precisely here that Addyi can be beneficial: it addresses a source of unease rather than a societal norm or performance pressure. This intimate fuel may aid approximately 1 in 10 women struggling with this condition, according to the International Society for Sexual Medicine.

Beyond the medical aspect, health professionals highlight the symbolic importance of this pill, as discussed in an article in SELF. They argue that Addyi challenges the notion that women’s intimate lives come to a grinding halt at menopause, as if desire were subject to an expiration date.

Its delayed entry into the market—compared to Viagra, which has been available since 1998—reflects long-standing stigmas surrounding female pleasure. “The availability of this option is a crucial acknowledgment that pleasure is significant for mature women,” states Dr. Rahman, “for both their quality of life and overall health.” Nonetheless, this pill should not become a “normal” prescription, dispensed indiscriminately in the pursuit of maintaining an active sex life or chasing an ideal of eternal youth.

A Medication to Approach With Caution

Every woman’s menopause experience is unique. Some may barely register its passage, while others feel alien in their own bodies. Beyond provoking caution, this Viagra competitor remains a chemical compound. In the United States, the only country where it is approved, a prescription is required to obtain it.

Those most affected can be hesitant about taking a pill that targets their brain and manipulates hormones. Specialists warn that it is not a miracle remedy destined to magically enhance the body or deceive one’s pleasure; it necessitates a personalized approach. Considering many women have taken contraceptive pills for years, often enduring their side effects, Addyi could perpetuate this cycle.

The challenge lies in positioning this pill as an option, never a disguised obligation. True progress is not just the existence of medication but ensuring women have the autonomy to decide, free from social and medical pressures, what they wish to rekindle, explore, or leave behind.